Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) Director Andrew Regan sold 150,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $0.33, for a total value of $49,500.00. Following the sale, the director now owns 15,214,091 shares of the company’s stock, valued at $5,020,650.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Andrew Regan also recently made the following trade(s):
- On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.26, for a total value of $393,666.00.
- On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $251,300.00.
- On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total transaction of $347,455.00.
- On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.51, for a total transaction of $18,320.73.
- On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.
Conduit Pharmaceuticals Trading Up 4.0 %
NASDAQ CDT opened at $0.14 on Friday. Conduit Pharmaceuticals Inc. has a fifty-two week low of $0.11 and a fifty-two week high of $22.00. The stock has a 50 day simple moving average of $0.17 and a two-hundred day simple moving average of $1.76.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.
View Our Latest Report on Conduit Pharmaceuticals
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Articles
- Five stocks we like better than Conduit Pharmaceuticals
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Best Aerospace Stocks Investing
- MarketBeat Week in Review – 9/16 – 9/20
- How to buy stock: A step-by-step guide for beginners
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.